Albutropin: Phase I

In an open-label, dose-escalating U.S. Phase I trial in 42 patients receiving either 10 ug/kg, 30 ug/kg, or 60 ug/kg, or two 60 ug/kg doses of seven days apart, 64% (9/14) of those patients given sing...